{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:49:54Z","timestamp":1761896994983,"version":"3.44.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T00:00:00Z","timestamp":1552348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.diabres.2019.02.023","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T11:59:36Z","timestamp":1552305576000},"page":"158-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs"],"prefix":"10.1016","volume":"150","author":[{"given":"Wenying","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Canan","family":"Ersoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guixia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shandong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Asirvatham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanti","family":"Werther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priti","family":"Kadu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2019.02.023_b0005","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJM198805123181903","article-title":"Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus","volume":"318","author":"Polonsky","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2019.02.023_b0010","doi-asserted-by":"crossref","first-page":"E67","DOI":"10.1152\/ajpendo.00529.2004","article-title":"Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes","volume":"290","author":"Woerle","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.diabres.2019.02.023_b0015","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2337\/dc18-Sint01","article-title":"Standards of medical care in Diabetes \u2013 2018","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2019.02.023_b0020","first-page":"447","article-title":"China T2DM prevention and treatment guideline (2013)","volume":"6","author":"Chinese Diabetes Society","year":"2014","journal-title":"Chin J Diabetes Mellitus"},{"key":"10.1016\/j.diabres.2019.02.023_b0025","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/dmrr.2827","article-title":"Standards of care for type 2 diabetes in China","volume":"32","author":"Weng","year":"2016","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.diabres.2019.02.023_b0030","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2337\/diacare.26.3.881","article-title":"Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c","volume":"26","author":"Monnier","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2019.02.023_b0035","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.amjmed.2013.06.011","article-title":"Intensifying insulin therapy: what options are available to patients with type 2 diabetes?","volume":"126","author":"Meneghini","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.diabres.2019.02.023_b0040","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2019.02.023_b0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pcd.2016.09.003","article-title":"Clinical inertia to insulin initiation and intensification in the UK: a focused literature review","volume":"11","author":"Khunti","year":"2017","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.diabres.2019.02.023_b0050","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1185\/03007995.2014.960512","article-title":"The SimpleMix study with biphasic insulin aspart 30: a randomized controlled trial investigating patient-driven titration versus investigator-driven titration","volume":"30","author":"Gao","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.diabres.2019.02.023_b0055","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1463-1326.2008.00915.x","article-title":"Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER study: a randomized controlled trial","volume":"11","author":"Liebl","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2019.02.023_b0060","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jdiacomp.2015.04.003","article-title":"Insulin glargine compared with premixed insulin for management of insulin-na\u00efve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study","volume":"29","author":"Aschner","year":"2015","journal-title":"J Diabetes Complic"},{"key":"10.1016\/j.diabres.2019.02.023_b0065","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/dom.12303","article-title":"Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial","volume":"16","author":"Tinahones","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2019.02.023_b0070","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/dom.12528","article-title":"Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape)","volume":"17","author":"Vora","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2019.02.023_b0075","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/1753-0407.12312","article-title":"Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: a 24-week randomized non-inferiority trial","volume":"8","author":"Jin","year":"2016","journal-title":"J Diabetes"},{"key":"10.1016\/j.diabres.2019.02.023_b0080","doi-asserted-by":"crossref","first-page":"852","DOI":"10.2337\/dc07-1992","article-title":"Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs","volume":"31","author":"Yang","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2019.02.023_b0085","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s13300-016-0199-2","article-title":"Initiation and intensification strategies in type 2 diabetes management: a comparison of basal plus and premix regimens","volume":"7","author":"Downie","year":"2016","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2019.02.023_b0090","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s12020-015-0718-3","article-title":"Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"51","author":"Giugliano","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.diabres.2019.02.023_b0095","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1111\/j.1742-1241.2009.02192.x","article-title":"Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement","volume":"63","author":"Unnikrishnan","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.diabres.2019.02.023_b0100","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1463-1326.2005.00563.x","article-title":"Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70\/30 (the 1-2-3 study)","volume":"8","author":"Garber","year":"2006","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822718308039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822718308039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:08:37Z","timestamp":1759172917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822718308039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":20,"alternative-id":["S0168822718308039"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2019.02.023","relation":{},"ISSN":["0168-8227"],"issn-type":[{"type":"print","value":"0168-8227"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2019.02.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}